Evidence map›Paper›PMID 38854109›Full record

ArticlebioRxiv : the preprint server for biology2024

Aggressive high-grade NF2 mutant meningiomas downregulate oncogenic YAP signaling via the upregulation of VGLL4 and FAT3/4.

Abigail G Parrish, Sonali Arora, H Nayanga Thirimanne, Dmytro Rudoy, Sebastian Schmid, Philipp Sievers, Felix Sahm, Eric C Holland, Frank Szulzewsky

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Abigail G ParrishHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Sonali AroraHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
H Nayanga ThirimanneHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-8016-3031
Dmytro RudoyHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Sebastian SchmidHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Philipp SieversDepartment of Neuropathology, Institute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Felix SahmDepartment of Neuropathology, Institute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.ORCID 0000-0001-5441-1962
Eric C HollandHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Frank SzulzewskyHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0001-5710-9590

Funding

The role and mechanism of alternative RNA splice variants and gene fusions as drivers of cancerR35CA253119 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric C. Holland · 2021 to 2026
$6.5M
Mechanisms and models of C11or95 and C11or95-RELA fusions (RELAFus )U54CA243125 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HOLLAND, ERIC C. · 2019 to 2022
$6.2M
NCI NIH HHS R35 CA253119NCI NIH HHS U54 CA243125
6 · The paper itself

Abstract

Meningiomas are the most common primary brain tumors in adults. Although generally benign, a subset of meningiomas is of higher grade, shows aggressive growth behavior and recurs even after multiple surgeries. Around half of all meningiomas harbor inactivating mutations in NF2. While benign low-grade NF2 mutant meningiomas exhibit few genetic events in addition to NF2 inactivation, aggressive high-grade NF2 mutant meningiomas frequently harbor a highly aberrant genome. We and others have previously shown that NF2 inactivation leads to YAP1 activation and that YAP1 acts as the pivotal oncogenic driver in benign NF2 mutant meningiomas. Using bulk and single-cell RNA-Seq data from a large cohort of human meningiomas, we show that aggressive NF2 mutant meningiomas harbor decreased levels YAP1 activity compared to their benign counterparts. Decreased expression levels of YAP target genes are significantly associated with an increased risk of recurrence. We then identify the increased expression of the YAP1 competitor VGLL4 as well as the YAP1 upstream regulators FAT3/4 as a potential mechanism for the downregulation of YAP activity in aggressive NF2 mutant meningiomas. High expression of these genes is significantly associated with an increased risk of recurrence. In vitro, overexpression of VGLL4 resulted in the downregulation of YAP activity in benign NF2 mutant meningioma cells, confirming the direct link between VGLL4 expression and decreased levels of YAP activity observed in aggressive NF2 mutant meningiomas. Our results shed new insight on the biology of benign and aggressive NF2 mutant meningiomas and may have important implications for the efficacy of therapies targeting oncogenic YAP1 activity in NF2 mutant meningiomas.

Identifiers

PMID38854109
PMCPMC11160807

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.